Ibrx stock forecast 2025 pipeline diversification plays a

Pipeline diversification plays a pivotal role in the IBRX stock forecast 2025 scenario, where multiple approvals may double projected cash flows, attracting long-term institutional portfolios. ImmunityBio is doing well on the financial side, as in Q3 2024, it made $6.0 million in product revenue, six times more than last quarter and outperforming analysts’ predictions. Starting January 2025, ANKTIVA has a permanent J-code, making it easier for Medicare and VA patients to get covered. ImmunityBio, Inc. (NASDAQ:IBRX) is also expanding globally, having applied for approval in the UK’s MHRA last November and planning for an EMA in the EU soon. https://www.businesswire.com/news/home/20250725253978/en/ Active coverage from Wall Street firms underscores confidence levels in IBRX’s 2025 outlook, positioning the stock among top watch-list candidates for biotech sector investors.